These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

5441 related items for PubMed ID: 16061582

  • 1. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM, Rhodes P, Connelly BL, Bi D, Hahn C, Patrick S, Glodé MP, Ehresmann KR, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA. kbisgard@cdc.gov.
    Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
    [Abstract] [Full Text] [Related]

  • 2. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.
    America Academy of Pediatrics Commitee on Infectious Diseases.
    Pediatrics; 2006 Mar; 117(3):965-78. PubMed ID: 16382131
    [Abstract] [Full Text] [Related]

  • 3. Evidence of efficacy of the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis vaccine but not the Lederle whole-cell component diphtheria and tetanus toxoids and pertussis vaccine against Bordetella parapertussis infection.
    Heininger U, Stehr K, Christenson P, Cherry JD.
    Clin Infect Dis; 1999 Mar; 28(3):602-4. PubMed ID: 10194085
    [Abstract] [Full Text] [Related]

  • 4. Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life.
    Knuf M, Habermehl P, Faber J, Bock HL, Sänger R, Bogaerts H, Clemens R, Schuind A, du Prel JB, Schmitt HJ.
    Vaccine; 2006 Jul 07; 24(27-28):5627-36. PubMed ID: 16740348
    [Abstract] [Full Text] [Related]

  • 5. Association between undervaccination with diphtheria, tetanus toxoids, and acellular pertussis (DTaP) vaccine and risk of pertussis infection in children 3 to 36 months of age.
    Glanz JM, Narwaney KJ, Newcomer SR, Daley MF, Hambidge SJ, Rowhani-Rahbar A, Lee GM, Nelson JC, Naleway AL, Nordin JD, Lugg MM, Weintraub ES.
    JAMA Pediatr; 2013 Nov 07; 167(11):1060-4. PubMed ID: 24019039
    [Abstract] [Full Text] [Related]

  • 6. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.
    Salmaso S, Mastrantonio P, Tozzi AE, Stefanelli P, Anemona A, Ciofi degli Atti ML, Giammanco A, Stage III Working Group.
    Pediatrics; 2001 Nov 07; 108(5):E81. PubMed ID: 11694665
    [Abstract] [Full Text] [Related]

  • 7. Dose-response to a two-component acellular pertussis vaccine in infants and comparison with whole-cell vaccine.
    Auerbach BS, Lake AM, Wilson ME, Willingham FF, Shematek J, Moulton L, Deforest A, Halsey NA.
    Biologicals; 1998 Jun 07; 26(2):145-53. PubMed ID: 9811522
    [Abstract] [Full Text] [Related]

  • 8. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine.
    Stehr K, Cherry JD, Heininger U, Schmitt-Grohé S, uberall M, Laussucq S, Eckhardt T, Meyer M, Engelhardt R, Christenson P.
    Pediatrics; 1998 Jan 07; 101(1 Pt 1):1-11. PubMed ID: 9417143
    [Abstract] [Full Text] [Related]

  • 9. How do physicians immunize their own children? Differences among pediatricians and nonpediatricians.
    Posfay-Barbe KM, Heininger U, Aebi C, Desgrandchamps D, Vaudaux B, Siegrist CA.
    Pediatrics; 2005 Nov 07; 116(5):e623-33. PubMed ID: 16263976
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine.
    Langley JM, Predy G, Guasparini R, Law B, Diaz-Mitoma F, Whitstitt P, Tapiero B, Dionne M, Tomovici A, Mills E, Halperin SA.
    Vaccine; 2007 Jan 22; 25(6):1121-5. PubMed ID: 17045366
    [Abstract] [Full Text] [Related]

  • 12. Case-control study of vaccination history in relation to pertussis risk during an outbreak among school students.
    Khan FN, Lin M, Hinkle CJ, Franklin P, Luther R, Woodruff F, Henson K, Lukenbill M, Gutierrez M, Zhu BP.
    Pediatr Infect Dis J; 2006 Dec 22; 25(12):1132-6. PubMed ID: 17133158
    [Abstract] [Full Text] [Related]

  • 13. Minor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group.
    Schmitt-Grohé S, Stehr K, Cherry JD, Heininger U, Uberall MA, Laussucq S, Eckhardt T.
    Dev Biol Stand; 1997 Dec 22; 89():113-8. PubMed ID: 9272341
    [Abstract] [Full Text] [Related]

  • 14. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine.
    Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J.
    N Engl J Med; 1996 Feb 08; 334(6):349-55. PubMed ID: 8538705
    [Abstract] [Full Text] [Related]

  • 15. Severe adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group.
    Uberall MA, Stehr K, Cherry JD, Heininger U, Schmitt-Grohé S, Laussucq S, Eckhardt T.
    Dev Biol Stand; 1997 Feb 08; 89():83-9. PubMed ID: 9272335
    [Abstract] [Full Text] [Related]

  • 16. The introduction of diphtheria-tetanus-pertussis vaccine and child mortality in rural Guinea-Bissau: an observational study.
    Aaby P, Jensen H, Gomes J, Fernandes M, Lisse IM.
    Int J Epidemiol; 2004 Apr 08; 33(2):374-80. PubMed ID: 15082643
    [Abstract] [Full Text] [Related]

  • 17. Effects of a minimum interval immunization schedule for diphtheria and tetanus toxoids and acellular pertussis vaccination during a pertussis outbreak.
    Bronson-Lowe D, Anderson SM.
    Arch Pediatr Adolesc Med; 2009 May 08; 163(5):417-21. PubMed ID: 19414686
    [Abstract] [Full Text] [Related]

  • 18. Comparative Efficacy of the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine and Lederle whole-cell component DTP vaccine in German children after household exposure. Pertussis Vaccine Study Group.
    Heininger U, Cherry JD, Stehr K, Schmitt-Grohé S, Uberall M, Laussucq S, Eckhardt T, Meyer M, Gornbein J.
    Pediatrics; 1998 Sep 08; 102(3 Pt 1):546-53. PubMed ID: 9738175
    [Abstract] [Full Text] [Related]

  • 19. Administration of tetanus, diphtheria, and acellular pertussis vaccine to parents of high-risk infants in the neonatal intensive care unit.
    Dylag AM, Shah SI.
    Pediatrics; 2008 Sep 08; 122(3):e550-5. PubMed ID: 18762489
    [Abstract] [Full Text] [Related]

  • 20. Simultaneous administration of Haemophilus influenzae type b vaccine with acellular or whole-cell pertussis vaccine: effects on reactogenicity and immune responses to pertussis vaccines.
    Rennels MB, Reed GF, Decker MD, Edwards KM, Pichichero ME, Deloria MA, Englund JA, Anderson EL, Steinhoff MC, Deforest A.
    Pediatrics; 1995 Sep 08; 96(3 Pt 2):576-9. PubMed ID: 7659479
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 273.